Lean: Targeted Therapy for Care Delivery

Lean: Targeted Therapy for Care Delivery.

Advances in cancer care have reached unprecedented milestones, but these achievements come at significantly high costs.1 Disorganized and uncoordinated care can harm patients and contributes to unsustainable expenses. The CMS Innovation Center is addressing these issues with financial incentives under the Oncology Care Model (OCM) umbrella that aims to provide higher quality and more coordinate...

Advances in Targeted Drug Delivery

Advances in Targeted Drug Delivery

Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.

INTRODUCTION The epithelial cell adhesion molecule (EpCAM) is abundantly expressed in epithelial tumors, on cancer stem cells and circulating tumor cells. Together with its role in oncogenic signaling, this has sparked interest in its potential for tumor targeting with antibodies and drug conjugates for safe and effective cancer therapy. Recent advances in protein engineering, linker design and...

Targeted, non-viral gene delivery for cancer gene therapy.

The ability to mediate targeted and specific delivery of therapeutics to cancer cells remains one of the most important hurdles in effectively treating cancer. This aspect also remains as one of the greatest limitations of gene therapy as well. Targeted vectors based on the use of DNA-binding agents attached to cell specific ligands or "molecular conjugates" were created with the goal of over-c...